Short-Term Opioid Withdrawal Using Buprenorphine

• This NIDA-SAMHSA-ATTC Blending Initiative product includes:

Brochure: Download or view it as a Adobe Acrobat publication (pdf)

Presentation: Download Powerpoint XP format (ppt) or
view it as a Adobe Acrobat publication (pdf)

Trainers Guider: Download or view it as a Adobe Acrobat publication (pdf)

• Product Introduction:

Opioid use and abuse continues to be a problem across the United States, in fact, research is showing opioid use is increasing. More than 3 million people over the age of 12 have used heroin at least one time and by doing so, more patients may be willing to seek treatment and will need access to treatment.

One answer in broadening access to treatment includes both office-based settings and medical detoxification units. Research suggests a buprenorphine taper was successful in both outpatient and inpatient settings and was superior to clonidine in both settings. In order to disseminate information to the addiction treatment field, the National Institute on Drug Abuse (NIDA) has created a partnership with the Addiction Technology Transfer Center (ATTC) Network which provides the dissemination product: Short-Term Opioid Withdrawal Using Buprenorphine. The product was designed to provide a broad overview of the two NIDA-CTN studies and to provide instruction for the implementation of these research findings.

• Blending Team Members:
  
  NIDA
  
• Gregory Brigham, PhD, Maryhaven Community Treatment Program
• Judith Harrer, PhD, VA Medical Center Community Treatment Program
• Dennis McCarty, PhD, Oregon Health Sciences University

SAMHSA/ATTC

• Chair: Thomas Freese, Ph.D., Pacific Southwest ATTC
• Beth Finnerty, MPH, Pacific Southwest ATTC
• Kay Gresham-Morrison, LCSW, ACSW, Southeast ATTC
• Susan Storti, PhD, RN, New England ATTC


• The first hand-off meeting was held July 19-20, 2005. Published date: Spring, 2005


• Training Objectives
• Describe opioid withdrawal and the role of medical interventions in it
• Understand the results of new research on one strategy for helping patients withdraw from opioid using buprenorphine

Return to Top of Page